MYC deregulation sensitizes cancer cells to N-myristoyltransferase inhibition
More about Open Access at the CrickAuthors list
Gregor A Lueg James Zhang Monica Faronato Andrii Gorelik Wouter W Kallemeijn Francesco Falciani Josephine Walton Jack W Houghton Silvia Vannini Evon Poon Barbara M Costa Roberto Solari Robin Carr Andrew S Bell Edward J Bartlett Bernadette Brzezicha Martin Janz Louis Chesler Dinis Calado Edward W TateAbstract
Human N-myristoyltransferases (NMTs) catalyze N-terminal protein N-myristoylation and are promising targets in cancer, with an emerging mechanistic rationale for targeted therapy. Here, we screened 245 cancer cell lines against IMP-1320, a potent NMT inhibitor (NMTi), and conducted pathway-level analyses to identify that deregulated MYC increases cancer cell sensitivity to NMTis. Proteomics on detergent-enriched membrane fractions in MYC or MYCN-deregulated cancer cell models revealed that cell death is associated at least in part with loss of membrane association of mitochondrial respiratory complex I. This is concurrent with loss of myristoylation and degradation of the complex I assembly factor NDUFAF4, and induction of mitochondrial dysfunction, driven by MYC or MYCN-deregulation. NMTis eliminated or suppressed MYC- and MYCN-driven tumors in vivo without overt toxicity, suggesting that this constitutive co-translational protein modification can be targeted in MYC-driven cancers.
Journal details
Journal
Cell Reports
Volume
44
Issue number
9
Pages
116180
Available online
Publication date
Full text links
Publisher website (DOI)
10.1016/j.celrep.2025.116180
Figshare
View on figshare
Europe PubMed Central
40849903
Pubmed
40849903
Keywords
Related topics
Type of publication
Publishing history
The publication was previously a preprint.
View preprint
